98%
921
2 minutes
20
The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts cardiac function through granulomatous infiltration of the heart, resulting in conduction disease, arrhythmia, and/or heart failure. The diagnosis of cardiac sarcoidosis (CS) can be challenging and requires clinician awareness as well as differentiation from overlapping diagnostic phenotypes, such as other forms of myocarditis and arrhythmogenic cardiomyopathy. Clinical manifestations, extracardiac involvement, histopathology, and advanced cardiac imaging can all lend support to a diagnosis of CS. The mainstay of therapy for CS is immunosuppression; however, no prospective clinical trials exist to guide management. Patients may progress to developing advanced heart failure or ventricular arrhythmia, for which ventricular assist device therapies or heart transplantation may be considered. The existing knowledge gaps in CS call for an interdisciplinary approach to both patient care and future investigation to improve mechanistic understanding and therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748280 | PMC |
http://dx.doi.org/10.1016/j.cardfail.2021.06.016 | DOI Listing |
Am J Cardiol
May 2025
MedStar Heart and Vascular Institute, MedStar Health, Washington, DC; Georgetown University School of Medicine, Washington, DC.
Int J Cardiol
December 2023
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Electronic address:
Endocr Pract
July 2022
Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, Florida. Electronic address:
Objective: We aimed to determine the prevalence and clinical characteristics of self-reported hyperthyroidism in patients with sarcoidosis.
Methods: A national registry-based study investigating 3836 respondents to the Sarcoidosis Advanced Registry for Cures questionnaire in the period between June 2014 and August 2019 was conducted. This registry is generated from a web-based questionnaire that is self-reported by patients with sarcoidosis.
Eur Thyroid J
January 2022
Univ. Grenoble Alpes, Department of Endocrinology, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Background And Objective: It has been reported recently in a cross sectional study that patients with amiodarone induced thyrotoxicosis (AIT) showed a 'white' thyroid on unenhanced computed tomography, due to intrathyroid iodine accumulation. However, the link between increase in thyroid radiologic density and amiodarone induced thyrotoxicosis remains unknown. We sought to analyze this link.
View Article and Find Full Text PDFOpen Heart
September 2021
Department of Cardiology, Saitama Cardiovascular and Respiratory Center, Kumagaya-City, Japan.
Objective: We investigated the diagnostic performance of semi-quantitative hyperintensity on T2-weighted short-tau-inversion-recovery black-blood (T2W-STIR-BB) images in identifying active cardiac sarcoidosis (CS) in patients, and compared it with that of F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET).
Methods: This retrospective study included 40 steroid-naive patients (age 63.1±12.